- Home
- ANGH vs AFMD Comparison
ANGH vs AFMD Comparison
Compare ANGH & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- AFMD
- Stock Information
- Founded
- ANGH 2012
- AFMD 2000
- Country
- ANGH United Arab Emirates
- AFMD Germany
- Employees
- ANGH N/A
- AFMD 78
- Industry
- ANGH Telecommunications Equipment
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- AFMD Health Care
- Exchange
- ANGH Nasdaq
- AFMD Nasdaq
- Market Cap
- ANGH 51.4M
- AFMD 43.3M
- IPO Year
- ANGH N/A
- AFMD 2014
- Fundamental
- Price
- ANGH $0.73
- AFMD $2.72
- Analyst Decision
- ANGH
- AFMD Strong Buy
- Analyst Count
- ANGH 0
- AFMD 5
- Target Price
- ANGH N/A
- AFMD $16.00
- AVG Volume (30 Days)
- ANGH 14.9K
- AFMD 132.2K
- Earning Date
- ANGH 12-24-2024
- AFMD 11-14-2024
- Dividend Yield
- ANGH N/A
- AFMD N/A
- EPS Growth
- ANGH N/A
- AFMD N/A
- EPS
- ANGH N/A
- AFMD N/A
- Revenue
- ANGH $41,380,440.00
- AFMD $6,287,085.00
- Revenue This Year
- ANGH N/A
- AFMD N/A
- Revenue Next Year
- ANGH N/A
- AFMD $48.98
- P/E Ratio
- ANGH N/A
- AFMD N/A
- Revenue Growth
- ANGH N/A
- AFMD N/A
- 52 Week Low
- ANGH $0.71
- AFMD $2.64
- 52 Week High
- ANGH $2.85
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- ANGH 40.13
- AFMD 26.78
- Support Level
- ANGH $0.71
- AFMD $3.16
- Resistance Level
- ANGH $0.78
- AFMD $4.04
- Average True Range (ATR)
- ANGH 0.05
- AFMD 0.30
- MACD
- ANGH 0.00
- AFMD -0.11
- Stochastic Oscillator
- ANGH 21.44
- AFMD 0.00
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.